Fingolimod Trials Update

Good news from a follow-up on the previously-mentioned fingolimod drug (from Medical News Today 1/10/09

Drug manufacturer Novartis has announced further results from its phase III study of the oral pill fingolimod (FTY-720) in people with relapsing remitting MS.

The results are from a two-year phase III study called FREEDOMS trial and show that the tablet can reduce relapses by up to 60% and disability progression by up to 32% in people with relapsing remitting MS.

The results build on trial data announced earlier in the year that showed a reduction in the number of relapses by about 58% in participants taking fingolimod compared to interferon-beta-1a, a standard injectable therapy for the treatment of relapsing remitting MS.

For more details check it under the Medical News Today link

ps. an update on the progress of Cladribine (the second oral drug used for MS) is also available through the same link for the same date.

Keep up the good spirit! : o)